Acorda Therapeutics (ACOR) Tops Q1 EPS by 12c; Updates on Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda (ACOR) Top-Line Growth Should Accelerate in H214; Aegis Affirms 'Buy' Rating
May 6, 2014 11:37 AM EDTAegis Capital affirms Acorda Therapeutics, Inc. (Nasdaq: ACOR) at Buy with a target price of $50 following Q1 results and update.
Analyst Ram Selvaraju commented, Non-GAAP earnings per share were $0.21, slightly below our forecast of $0.24; however, GAAP earnings per share were $0.02, following the impact of a... More
